We scan new podcasts and send you the top 5 insights daily.
When selecting initial ADC therapy for ovarian cancer patients with dual biomarker expression (FR-alpha positive and HER2-positive), clinicians favor starting with mirvetuximab soravtansine over trastuzumab deruxtecan. Initiating mirvetuximab captures its proven overall survival advantage while keeping trastuzumab deruxtecan available as an effective option for subsequent sequencing.
The introduction of ADCs into frontline ovarian cancer treatment creates a new challenge: conflicting biomarkers. A patient's tumor might be positive for both HER2 (an ADC target) and a BRCA mutation (a PARP inhibitor target), forcing clinicians to choose between two effective targeted therapies without clear guidance.
Early clinical trial data suggests that topoisomerase-1 payload ADCs retain efficacy in patients previously treated with mirvetuximab. Because mirvetuximab has a different cytotoxic payload, this indicates that targeting the same receptor (FR-alpha) with a different type of toxin is a viable sequencing strategy.
The treatment landscape for platinum-resistant ovarian cancer has rapidly evolved into a biomarker-driven paradigm. Clinicians must now test for and choose between therapies targeting distinct markers like folate receptor alpha (mirvetuximab), HER2 (T-DXd), and PD-L1 (pembrolizumab), requiring a sophisticated sequencing strategy.
The B96 trial's potential approval for platinum-resistant ovarian cancer introduces a new treatment sequencing challenge. Clinicians must decide between this immunotherapy combination and the ADC mervituximab, which has a clear biomarker (foliate receptor alpha). The lack of a reliable biomarker for the B96 regimen complicates this decision-making process for patients.
Concordance between local and central HER2 testing for ovarian cancer is poor. However, early data suggests the T-DXd antibody-drug conjugate is effective regardless of this variability, meaning any positive signal could be clinically actionable for this difficult-to-treat cancer.
Unlike early ADCs requiring high biomarker expression (e.g., mirvetuximab), next-generation agents show efficacy even in low-expressing tumors. This allows for broader, "all-comer" clinical trial inclusion criteria instead of biomarker-gated entry, potentially expanding patient access to these novel therapies.
The ADC mirvetuximab is the first drug to demonstrate an overall survival benefit for platinum-resistant ovarian cancer. This groundbreaking result establishes a higher efficacy standard that subsequent therapies will likely need to meet for regulatory approval and clinical adoption, raising the bar for future drug development.
Patients whose ovarian cancer progresses on the folate-targeted ADC mirvetuximab may still respond to a subsequent folate-targeted ADC with a different cytotoxic payload. This suggests that the folate receptor alpha target remains viable and that resistance may be payload-specific, opening new sequencing strategies.
Despite concerns about cross-resistance from breast cancer data, experts would consider sequencing ADCs with the same payload (e.g., deruxtecan). The rationale is that even a diminished response rate (e.g., 30%) is still significantly better than the 15% seen with standard single-agent cytotoxics.
With multiple new effective options in platinum-resistant disease (relacorilant, pembrolizumab, ADCs), the key clinical question is shifting from choosing one superior drug to determining the optimal sequence. Biomarkers can guide initial choices, but sequencing multiple regimens, including re-using weekly paclitaxel backbones, is now a viable strategy.